Compare RENT & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RENT | BDTX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.6M | 104.0M |
| IPO Year | 2021 | 2020 |
| Metric | RENT | BDTX |
|---|---|---|
| Price | $2.27 | $1.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 135.9K | ★ 761.0K |
| Earning Date | 12-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 110.16 | ★ 130.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $329,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.71 | N/A |
| 52 Week Low | $1.51 | $1.60 |
| 52 Week High | $10.13 | $4.94 |
| Indicator | RENT | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.11 | 50.64 |
| Support Level | $1.51 | $1.79 |
| Resistance Level | $3.91 | $1.93 |
| Average True Range (ATR) | 0.17 | 0.12 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 86.92 | 57.26 |
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe to, or buy designer apparel and accessories. The company gives customers access to its unlimited closet through its subscription offering (Subscription) or the ability to rent a-la-carte through its reserve offering (Reserve). The company also gives its subscribers and customers the ability to buy its products through its Resale offering. The Closet in the Cloud offers a wide assortment of items for every occasion, from evening wear and accessories to ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear, and ski wear.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.